Podcasts about dmd

EP 342: The MARPE Experience – Bodywork, Diet, and the Mind-Body Connection in OrthodonticsIn this engaging conversation, Hallie Bulkin and Jeannie Nelson discuss their upcoming Marpe procedures, sharing their personal experiences, expectations, and the challenges they anticipate. They delve into the intricacies of the Marpe process, the importance of bodywork and therapy, dietary considerations post-procedure, and the psychological aspects of pain management. The discussion also touches on the impact of hormonal changes on pain perception, the significance of airway health, and the aesthetic changes they hope to achieve. Throughout the conversation, they emphasize the journey of orthodontics as a holistic process that goes beyond just physical changes, highlighting the interconnectedness of body, mind, and health.In this episode, you'll learn:✔️Both hosts are undergoing Marpe procedures within 24 hours of each other.✔️The Marpe procedure involves local anesthesia and is not a surgical procedure.✔️Personal goals for the procedure include improved airway health and aesthetics.✔️Orthodontics is more than just straightening teeth; it involves overall health.✔️Bodywork and therapy play a crucial role in the orthodontic journey.✔️Dietary changes will be necessary post-procedure to accommodate healing.✔️Pain management strategies are important for both hosts as they prepare for their procedures.✔️The journey of orthodontics is a holistic process that requires patience and understanding. RELATED EPISODES YOU MIGHT LOVEEp 331: Inside My MARPE Journey with Hallie Bulkin, MA, CCC-SLP, CMT®, CPFT™Ep 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSOTHER WAYS TO CONNECT & LEARNVisit : https://www.breatheeatsleeptalk.com/

The DMD is here on a Friday! Let's get going!

The DMD is here! And we are ready to chat MARINERS TURNSTILE AND SO MUCH MORE!

Happy Birthday Migs! Plus the DMD is here and we chat with Seahawks' Abe Lucas!

Want to Support the Show? Visit Our Patreon at or pick up a tee shirt at Silverball Swag  Check out Flip N Out Pinball for all your pinball needs! Topic begins at 12:28   Episode Summary:   Pinball has had a dramatic change since the end of the modern DMD era at Stern. The designers we all know and love from the 80s and 90s have begun to retire, slow down, or leave the industry. A new wave of designers has started to slide in and learn from the masters… The first major new designer to come along was the tournament player Keith Elwin.   Some say Keith Elwin is the second coming of our lord and saviour Steve Ritchie. Others say ‘in Elwin we trust'… but is that all hype? Has Keith Elwin changed the pinball designer game as much as some believe?   Join us this month as we chat about the second coming golden age of pinball, Keith's dominance of tournament pinball, his deep understanding of repair, play, code, and design, his first pin, and his second smash hit follow-up!   Sources: Kineticist Keith Elwin Profile Head2Head Pinball Podcast Ep. 45 - Iron Maiden Head2Head Pinball Podcast Ep. 106 - Jurassic Park Just Another Pinball Podcast - Godzilla  Flip N Out Podcast with Joel E - Jaws Loser Kid Podcast - King Kong Pinside Keith Elwin Designer Profile

Ever wonder what really goes on in the minds of dentists considering a major practice overhaul? In this episode, your hosts pull back the curtain on the emotional journey they witness at their events. They share observations ranging from initial skepticism and hesitation to genuine gratitude and excitement as attendees realize the potential of the firm's services.We dive deep into why being coachable, vulnerable, and self-aware isn't just a soft skill—it's the single most important factor for dentists looking to unlock their practices' profitability and long-term viability. Listen in to learn what it takes to stop resisting change and start building the practice of your dreams.Interested in more info on how to: Earn More, Save More, and Retire EarlyUpcoming Tour Dates: Go to our EVENTS page for infoFacebook: Four Quadrants AdvisoryInstagram: @fourquadrantsadvisoryLinkedIn: Four Quadrants Advisory

Happy Tuesday the DMD is here! Let's chat about that COSTCO Executive status!

The DMD is here! Let's chat Savannah Bananas!

“I want people to look at their toothpaste just like they look at their food labels,” says Staci Whitman, DMD.  Staci Whitman, DMD, board-certified pediatric dentist and a leader in functional dentistry, joins us today to share science-backed insights on how your oral health influences your whole-body health, and the simple steps you can take to optimize it:  - Oral health is the cornerstone of longevity (~3:00)  - Oral health & cognitive function (~4:30) - Testing (6:00) - Symptoms of oral dysbiosis (~10:00) - Nutrition for oral care (~12:00) - The importance of nasal breathing (~14:30) - Flossing & water picks (~15:00) - The impact of ultra-processed foods (~16:00) - Her daily routine (~17:00) - How to find the best products (~21:00) - The truth about fluoride (~25:00) - What is dental fluorosis? (~30:00) - Hydroxyapatite &  theobromine (~31:00) - Her oral healthcare line, Fygg (~33:00) - The case against mouthwash (~34:45) - How to drink coffee to protect your teeth (~37:00) - How to whiten your teeth (~38:00) - The risks of veneers (~42:30) - Root canal experiences (~43:15) - The Institute of Functional Dentistry (~52:00) Referenced in the episode:  - Follow Whitman on Instagram (@doctor_staci & @feedyourgoodguys) - Check out her website (https://doctorstaci.com/)  - Use code MBG20 for 20% off a purchase at fygg.com (one-time and subscription) This episode of the mindbodygreen podcast was created in partnership with MassMutual. MassMutual believes in helping people live well—so they can live more. Learn more at MassMutual.com/Wellness. We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has made a significant move in the pharmaceutical industry by acquiring 89bio for $3.5 billion, with a contingent value right of $6 per share. The acquisition includes pegozafermin, an analog in late-stage development for metabolic dysfunction-associated steatohepatitis. Meanwhile, former CDC director Susan Monarez spoke to the Senate about her firing, alleging that Health Secretary Robert F. Kennedy Jr. accused CDC employees of "killing children." In other news, Roivant and Pfizer's therapy shows promise in a rare inflammatory condition, BMS and Novo Nordisk have announced layoffs in New Jersey, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. Additionally, Lexicon has backed phase III decision for a non-opioid pain medication, and Rosnilimab shows promise as a potential next-generation treatment for rheumatoid arthritis. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies like Arsenal and X4 laying off staff to cut costs.The FDA is cracking down on pharmaceutical advertisements in a new regulatory initiative, targeting loopholes in direct-to-consumer ads. Experts believe the FDA is focusing on the wrong issues and should instead address the lack of regulations for compounder drug ads. Akeso, a biotech company in China, has seen success under CEO Michelle Xia's leadership. Other news in the pharmaceutical industry includes the rise of predictive care powered by consumers and AI, ongoing prescriptions of Sarepta's DMD gene therapy despite safety concerns, and companies like Sanofi pulling back from the UK market. Pharma companies are facing challenges in navigating uncertain times amidst layoffs and regulatory crackdowns. Stay tuned for more updates on the latest developments in the industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo's amylin analog drug, cagrilintide, has shown a significant 11.8% weight loss in a phase III trial, with improved safety data to address past tolerability issues. The FDA is set to make a decision on the drug, with significant stakes for the company and the Barth Syndrome community. Additionally, Sarepta's DMD gene therapy is still being prescribed by doctors despite safety concerns, and new members have been appointed to the ACIP panel. Stealth Biotherapeutics is awaiting a verdict on their potential treatment for Barth Syndrome, while Sino Biological's high-throughput platform for AI-driven antibody discovery offers promise for advancing therapeutic candidates. Novo and Lilly are competing for market leadership in obesity treatment, while Sanofi and other pharma companies are pulling back from investments in the UK. The pharmaceutical industry is navigating uncertainty during turbulent times.

This week, the Dental Amigos welcome Stephanie Mapp, DMD, dental consultant, speaker, and founder of “Mapp Your Practice.” With over 30 years of clinical and business experience, Dr. Mapp helps dentists navigate PPOs, practice transitions, and sustainable growth strategies. In this episode, Dr. Mapp shares her journey as a multi-practice owner navigating financial and legal adversity. With the knowledge gained from this experience, she now empowers dentists to rethink PPO participation, associate hiring, and practice profitability with clarity and resilience. To learn more about Dr. Mapp and ”Mapp Your Practice,” visit www.mappyourpractice.com. Listeners who want to reach Paul can do so at Paul@DentalNachos.com and those who want to reach Rob can do so at Rob@RMontgomery-law.com.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Capsida has reported a patient death in a gene therapy trial for epilepsy, but the exact cause of death has not been disclosed. The patient had received the gene therapy cap-002. ## The FDA is looking to streamline the development of non-opioid painkillers, while Avidity has seen functional improvements in their DMD therapy. ## The White House is reportedly considering restrictions on Chinese licensing deals in the pharmaceutical industry. ## Lilly is seeking individuals willing to challenge the status quo of medicine. ## Merck has abandoned a $1.3 billion R&D center in London, resulting in layoffs. Novo has cut 9,000 employees, and New York City's life sciences scene is growing. Thank you for tuning in to today's episode of Pharma and Biotech daily. Stay informed and have a great day!

On this episode, hosts Casey Hiers and Jarrod Bridgeman tackle a topic many dentists would rather avoid: the unexpected death of a practice owner. They stress the critical need for proactive financial and estate planning, not just to protect your business but also to spare your loved ones from a complicated and stressful process.Jarrod and Casey emphasize the immense value of having a comprehensive team in place to manage both your personal and professional affairs. They share real-world examples of how their clients' foresight has protected their practices and families, ensuring a smooth transition during an otherwise difficult time. Tune in to learn how to secure your legacy and give your loved ones peace of mind.Interested in more info on how to: Earn More, Save More, and Retire EarlyUpcoming Tour Dates: Go to our EVENTS page for infoFacebook: Four Quadrants AdvisoryInstagram: @fourquadrantsadvisoryLinkedIn: Four Quadrants Advisory

The DMD is here! DAILY MIGS DOWNLOAD! Plus we chat all about the PHILLIES KAREN!

Nick White, DMD, of Lake Mary Pediatric Dentistry, shares insights on dealing with staff shortages and current trends in the dental industry. He discusses taking a hands-on approach to new technology and offers advice for success for emerging leaders in the DSO space.

Nick White, DMD, of Lake Mary Pediatric Dentistry, shares insights on dealing with staff shortages and current trends in the dental industry. He discusses taking a hands-on approach to new technology and offers advice for success for emerging leaders in the DSO space.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne," Barry Byrne, MD, chief medical advisor at the Muscular Dystrophy Association and director of the Powell Gene Therapy Center at the University of Florida, discusses newly published consensus guidelines from the MDA and Parent Project Muscular Dystrophy on the safe delivery and monitoring of gene therapy in Duchenne muscular dystrophy (DMD). Byrne explains the rationale behind convening a global panel of experts, emphasizing the need for standardized practices in patient selection, administration, and follow-up care as gene therapy becomes more widely available. He highlights the importance of expanded multidisciplinary teams—including hematology, cardiology, nephrology, and immunology—in managing immune-related safety concerns, with particular attention to monitoring liver inflammation and emerging strategies such as rapamycin use. In addition, Byrne outlines how these guidelines address real-world challenges around access, including geographic barriers, language considerations, and financial constraints, while underscoring their role in shaping future gene therapy approaches as additional therapies move through development. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:00 – Why consensus guidelines were needed for gene therapy in DMD 2:10 – Top-line clinical considerations from the published recommendations 4:30 – Protocols for monitoring and managing adverse events, especially liver toxicity 6:30 – Neurology News Network 8:30 – Addressing health equity, language access, and financial barriers in gene therapy care 12:00 – How these recommendations may shape the future of DMD treatment The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Elijah Stacy, founder of Destroy Duchenne, speaks with Kevin Counterman, author of Breakfall, along with Buddy and Alan, about their new book. Breakfall is inspired by Kevin's late brother, Michael, and tells the story of Rudy and the Gallagher family, exploring themes of legacy, resilience, and the impact of Duchenne muscular dystrophy on the whole family.Learn More about Breakfall: https://breakfallbook.comWant to be on the podcast? Click here: https://www.destroyduchenne.org/podca…Learn more about the Destroy Duchenne Podcast here: https://www.destroyduchenne.org/podcastWebsite: https://www.destroyduchenne.orgSocial Media: Facebook:   / destroyduche.  .Instagram:   / destroyduch.  .Twitter: https://twitter.com/destroydisease?la...LinkedIn:   / dest.  .ABOUT DESTROY DUCHENNE PODCAST:A podcast telling the stories of those affected by a fatal muscle-wasting disease, Duchenne muscular dystrophy (DMD), that robs children of their ability to walk by the age of 11, the ability to raise their arms by their teenage years, and eventually their lives in their early 20s.Hosted by 24-year-old founder of the 501(c)3 nonprofit organization Destroy Duchenne, Elijah Stacy, who also suffers from Duchenne muscular dystrophy.The goal of the Destroy Duchenne podcast is very simple, yet ambitious: interview every person that has a relationship to Duchenne—people with Duchenne, parents, family members, friends, teachers, doctors—and tell their story to the world.Destroy Duchenne is a registered 501(c)3 nonprofit organization with the mission: to Complete the Cure for Duchenne muscular dystrophy by advancing medical technologies into human practice.Federal Tax ID: #82-3268952#Breakfall

Send us a textArtificial Intelligence is the future of dentistry, and we're so excited to get the inside scoop straight from the source, Dr. Greg Wu of Mango Voice

Host Dr. Joel Berg speaks with Dr. Chelsea Fosse, Vice President of the AAPD Research and Policy Center (RPC) on the current hot topics in public health and how the RPC is working to make an impact. They delve into how pediatric dentistry can continue to lead the way among the other dental specialties and with our medical peers on care for those children and adults with disabilities and other special healthcare needs. Dr. Fosse also shares how AAPD members and other healthcare professionals can turn to the RPC for support with state-specific questions relating to Medicaid or other legislation. Guest Bio: Chelsea Fosse, DMD, MPH is the Vice President, Research & Policy Center at the American Academy of Pediatric Dentistry (AAPD). She is boarded in dental public health. Before shifting her career to work in oral health policy research, she worked as a general dentist treating adults with disabilities. At AAPD, Chelsea leads a team focused on Medicaid policy and program administration, evidence-based dental care, access to high quality and safe dental care, the pediatric dental workforce, and other contemporary issues in oral health, public health, and health policy. She was previously at the American Dental Association (ADA) Health Policy Institute (HPI) where she led policy analysis for issues related to Medicaid and studied the oral health workforce and the industry's response to the COVID-19 pandemic. Before dental school, she worked in the Division of Children with Special Needs at the American Academy of Pediatrics. She currently serves as President of the Board of Directors at Well Child Center, a community-based organization offering WIC, dental, and other social and health services in Elgin, IL. Chelsea received her bachelor's from The University of Texas in 2009, DMD from Rutgers in 2017, and MPH from Columbia University in 2019. She completed a general practice residency at Helen Hayes Hospital in 2018 and a dental public health residency at Jacobi Medical Center in 2020. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The DMD is here! Daly Migs Download! Also we chat about your first job!

The DMD is here! DALY MIGS DOWNLOAD! We also chat with Taryn's hitchhiker!

In our latest podcast, Dr. Schmidt talks with Mitch Gardiner, DMD, FAGD, focused on dental malpractice and the role of expert witnesses in civil court cases, with discussions about the qualifications and objectivity required of dental experts. The conversation covered key elements needed to prove negligence in dental cases, including standards of care and proper documentation of patient interactions and treatment plans. Dr. Gardiner provided advice for young dentists on maintaining high standards of care through continuous education and proper record-keeping. Dr. Gardiner is a full-time general dentist practicing in a multi-specialty office. A 1977 graduate of The University of Medicine and Dentistry of New Jersey, Dr. Gardiner served for three years as a dental officer in the Navy. He is a clinical instructor on the teaching faculty of the Rutgers School of Dental Medicine in the Department of Restorative Dentistry-Fixed Prosthodontics. He has over 25 years of experience in reviewing dental malpractice cases as an expert witness. Dr. Gardiner lectures and presents programs on issues of dental malpractice throughout the United States. He holds fellowships in the Academy of General Dentistry, American College of Dentists and International College of Dentists.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA therapies beyond silencing.In other news, the disappointment of oral obesity therapies is discussed, with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics' VK2735 were underwhelming, leading to increased interest in weight loss pills in low- and middle-income countries. Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment, while a study in JAMA contradicts claims of corruption in vaccine advisory committees. Updates on cancer, cell and gene therapy are also provided.Stay tuned for more updates and feel free to suggest topics for future coverage.

The DMD is here! Let's get ready and hit this Monday hard! Plus Taryn picked up a hitchhiker?!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA is pushing new guidelines for cancer trials, recommending overall survival as a primary endpoint. Capricor Therapeutics is asking the FDA to reconsider their rejection of a treatment for DMD cardiomyopathy with the return of Vinay Prasad. Rocket Pharmaceuticals' phase II trial has resumed after a patient death, and the Trump administration's tariffs and drug pricing policies are causing confusion in the pharmaceutical industry. Fedegari is now offering customized solutions for the bio/pharmaceutical industry. The American Academy of Pediatrics is recommending the COVID-19 vaccine for kids, and there are updates on various biotech developments. Opinion pieces discuss drug pricing and the viability of high-dose peptides.The American pharmaceutical industry has lost the trust of the people, with many viewing them as the 'bad guys' despite producing drugs in the U.S. for Americans. The industry faces challenges such as competition and changing regulations, with the Trump administration's trade policies adding to the confusion. Some companies are taking a platform strategy approach to drug development, using one molecule to target multiple diseases. Despite these challenges, there are opportunities for innovation and growth in the industry. Additionally, conflicts of interest in vaccine committees have been decreasing, and companies are making strategic moves such as forming partnerships and restructuring to adapt to the changing landscape. The industry continues to navigate uncertainty and seek ways to improve drug development and access for patients.

The DMD is here! And school is almost started!

Ep 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSThis week on The Untethered Podcast™, Hallie welcomes back Dr. Svitlana Koval, Florida's leading provider of Miniscrew-Assisted Rapid Palatal Expansion (MARPE). Together, they explore the powerful connection between dental expansion, airway health, and facial balance covering MARPE and clear aligner mechanics, Hallie's personal experience with her children's treatment, timelines, post-care, and the transformative outcomes of a holistic approach.If this episode resonates with you, snap a screenshot of you listening and share it on your Instagram Stories! Tag Hallie @halliebulkin and @drsvitlanakoval to spread the word.In this episode, you'll learn:✔️ Clear Aligner (e.g., Invisalign) Journey and Airway Health✔️ Personal Experience with MARPE and Facial Asymmetry✔️ Understanding MARPE: Procedures and Techniques✔️ Comparing Traditional Expanders and MARPE✔️ Timeline and Procedures for Adult Expansion✔️ Understanding Bone Remodeling and Expansion Techniques✔️ Aesthetic Considerations in Orthodontic Treatment✔️ Timeline for Appliance Removal and Bone Fusion✔️ Impact of Expansion on Facial Structure✔️ Addressing Concerns with Mini Screws and TADs✔️ In-Office Procedure Insights and Patient Care✔️ Managing Asymmetries in Facial StructureRELATED EPISODES YOU MIGHT LOVEEp 263: Breathing Easy – Link Between Orthodontics, Speech & Health with Dr. Svitlana Koval & Tiffany ZilbermanEp 331: Inside My MARPE Journey with yours truly, Hallie BulkinABOUT TODAY'S GUESTI am so excited for you to meet Dr. Svitlana Koval! You can hang out with her over on Instagram and check out her practice at drssk.com.✨ FREE TRAINING ALERT – HAPPENING SEPTEMBER 8–10!If you're an SLP, OT, or student… you need to join me for the FREE 3-Day Pediatric Feeding Screening Training. Over 34,000 of your colleagues have done it — now it's your turn!Here's what you'll get when you sign up:4 hours on a certificate of completion (perfect for your renewal hours)My complete pediatric feeding screening packet — development chart, 50-symptom checklist, findings chart & referral formA chance to win one of FOUR full scholarships to the 12-week Feed The Peds® courseGrab your spot here → www.feedthepeds.com/trainingOTHER WAYS TO CONNECT & LEARN

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs enable read-through of premature stop codons to restore full-length protein production in genetic diseases. Fischer, whose daughter has Dravet syndrome, covers the company's lead programs in dilated cardiomyopathy and DMD, advantages over traditional gene therapy approaches, and the path to human proof-of-concept.

In this enlightening episode of the Living to 100 Club Podcast, Dr. Joseph Casciani welcomes Dr. Whitney Deitz, National Clinical Director of Aspen Dental. Together, they explore the powerful connection between oral health and cognitive decline. Dr. Deitz shares insights into how periodontal disease may increase the risk for Alzheimer's and dementia. Also discussed are the challenges of maintaining dental hygiene in individuals with reduced dexterity and the critical role of prevention throughout the lifespan. Listeners will learn about: The role of bacteria like P. gingivalis in periodontal disease and its potential link to dementia. The importance of maintaining oral health for dignity, pleasure, and overall well-being in later life. Practical dental care strategies for older adults and their caregivers, including tools like the Oral-B Genius and Callis Curve toothbrushes. How dry mouth, tooth loss, and limited mobility can all contribute to declining oral health and cognitive outcomes. Join us as we uncover why oral health isn't just about teeth – it's about quality of life, cognitive health, and healthy longevity. Mini Bio Whitney L. Deitz, DMD, is a practicing dentist and practice owner with Aspen Dental, serving communities in Owensboro, Madisonville, and Bowling Green, Kentucky. She also partners with offices in Hopkinsville and Paducah, Kentucky.  A 2015 graduate of the University of Kentucky College of Dentistry, Dr. Deitz received the Robert Henry Geriatric Dentistry Award for her dedication to geriatric oral care. She then completed a residency with focus on special populations and medically compromised patients.  She joined Aspen Dental in 2016 and has since become known for her commitment to comprehensive dental care and a patient-first approach. Her clinical expertise has been recognized at the 2024 Denobi Awards Gala, where she and her lab technician were honored for their contributions to dentistry. Specifically, Dr. Deitz helped set a global record by delivering the youngest-ever set of dentures to a then two-year-old. Her work inspired Aspen Dental to pursue a formal partnership with the National Foundation for Ectodermal Dysplasias, now known as The Smile Bridge by The Aspen Group. For Our Listeners Dr. Deitz' website: AspenDental.com

"My friends are toys. I make them. It's a hobby. I'm a genetic designer." This is a two part podcast covering the important factors is successful gene therapy and introduces the knowledge gained from other neuromuscular diseases and how it can be used to positively impact gene therapy in FSHD. In part 1, we focus on AAV serotypes, transgene constructs, immune responses, and delivery. We look into DMD gene therapy and how that can impact the current FSHD gene therapy programs. Check us out on the MyFSHD Youtube channel as well.

The DMD is here! And we wanna talk about all the things! Let's get it going!

The DMD is here! And we chat about what to pack to go to Austin. And we chat about Sturgis.

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple patient deaths. In this week’s episode of "The Top Line," we explore Sarepta’s brief standoff with the FDA over Elevidys, a short-lived marketing pause, and the regulator’s surprise reversal on the treatment. Fierce Pharma’s Fraiser Kansteiner and Angus Liu sit down with Fierce Biotech’s Gabrielle Masson to recap the story and discuss the broader implications the Elevidys saga may have for gene therapy, the FDA and the pharmaceutical industry. To learn more about the topics in this episode: Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Sarepta, bowing to FDA pressure, pauses shipments of Duchenne gene therapy Elevidys FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe See omnystudio.com/listener for privacy information.

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

The DMD is here! And we are playing music from all over the place for donations of $169!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the top biopharma venture capital raises of H1 2025 are summarized. Despite challenges like layoffs and market fluctuations, GSK remains committed to investing in the US despite tariffs. Other headlines include Madrigal's potential $2 billion investment, Biogen and Eisai's Alzheimer's drug update, and Novo Nordisk's new leadership. Trilink Biotechnologies is offering self-amplifying RNA constructs for potential therapeutic advancements.AI biotech companies have secured substantial funding in the first half of 2025, with continued investment pouring into startups within the industry. The top five biopharma venture capital raises of this period are highlighted. There is confusion surrounding Ira's definition of 'drug,' potentially hindering companies from pursuing approval for new formulations and indications. Vinay Prasad's departure from the FDA's Center for Biologics Evaluation and Research, following controversies related to Sarepta, has raised concerns among developers. Despite challenges, four biotech companies are successfully launching their products independently.Over 260 million people are impacted by rare diseases, emphasizing the need for faster evidence generation through global real-world data. GSK's commitment to investing in the US, Merck's cost-cutting measures to support its launch schedule, and Novo Nordisk's new leadership are also highlighted. The FDA has updated regulations regarding Sarepta's DMD gene therapy, making it available for ambulatory patients. Adaptimmune anticipates significant staff reductions following a cell therapy asset sale. Stay tuned for more updates on the latest developments in the biopharma industry.

In the latest podcast, Dr. Schmidt talks with Ralph Cooley, DDS, FAGD, and Arlene O'Brien, DMD, FAGD, who are members of ADA Legislative and Government Affairs Council and AGD representatives to the ADA Code Maintenance Committee. The Code Maintenance Committee is responsible for reviewing and updating dental coding systems. In their roles, they advocate for changes that benefit general dentists. New codes for 2026 include updates to anesthesia codes, a new cracked tooth testing code, and modifications to denture duplication and occlusal guard cleaning codes. They emphasize the importance of public input and collaboration between organizations. Listen now.

The DMD is here! And we chat about the staff's favorite OZZY and Black Sabbath songs!

Last week's public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene therapy Elevidys, a move the biotech has resisted. The deaths, and disputes between FDA and Sarepta, raise questions about the future of AAV gene therapies, as well as the future of FDA's platform technology designation. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the events surrounding Sarepta's gene therapies and discuss how FDA, industry and patient groups should come together to learn the lessons from the tragic, avoidable deaths.BioCentury's analysts also assess Monday's appointment of Stanford professor and biotech executive George Tidmarsh to lead FDA's Center for Drug Evaluation and Research, and check in on the latest trends in venture financings. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656537#biotech #biopharma #pharma #lifescience #GeneTherapy #AAVTherapy #Sarepta #Elevidys00:01 - Sponsor Message: IQVIA Biotech02:03 - Gene Therapy17:59 - Leading CDER27:00 - Venture ReportTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

The DMD is here! Sounders tied. Mariners didn't play, and we talk calling people the wrong name!

The DMD is here! We love informing you! Plus let's chat about going to the zoo!

THE DMD is here! And we are ready to go! Cal Raleigh won the HOMERUN DERBY!

The DMD is here! And we wanna chat with you about CAMPING!

Happy Thursday! The DMD is here and we are talking swear words! Plus donate now to Kicks for Kids at KISW.com!

THE DMD is here! Are you ready! Let's also chat about what you stole?

The DMD is here on a Tuesday! Plus we chat about rockstar names!

Happy Wednesday! The DMD is here! Let's chat about The Mariners losing.

The DMD is here! And let's chat about what your kid did for you!